A study using brain imaging and biomarker data identified three distinct patterns of cognitive decline in people with preclinical Alzheimer's disease.
Key Details
- 1Researchers analyzed 6-year data from the A4 and LEARN studies, involving people with preclinical Alzheimer's.
- 2Three cognitive trajectories were identified: stable, slow decline, and fast decline; 70% of participants remained stable.
- 3Higher baseline levels of phosphorylated tau (P-tau217) and brain scan tau markers, as well as smaller hippocampal volumes, predicted greater cognitive decline.
- 4Biomarker models could predict stable vs. declining status with about 70% accuracy.
- 5Findings suggest many clinical trial participants do not decline, complicating drug effect measurement.
Why It Matters
The study advances understanding of heterogeneity in Alzheimer's progression and highlights the potential for imaging biomarkers (e.g., PET, MRI) to inform prognosis and participant selection in clinical trials. Improved prediction via imaging and AI could optimize trial design and enable more personalized care in neurodegenerative disease.
Source
EurekAlert
Related News
•EurekAlert
Peking University Debuts LargePNet for Superior Fluorescence Image Restoration
Peking University's Xi Peng lab introduces LargePNet, a new AI for robust fluorescence image restoration, outperforming patch-based methods.
•EurekAlert
AI Detects Smuggled Marine Life in Airport CT Scans
Researchers developed an AI algorithm to identify smuggled marine wildlife in airport luggage using CT scans with high accuracy.
•EurekAlert
AI Predicts Brain Tumor Risks from Routine Pathology Slides
Mayo Clinic developed an AI that analyzes routine pathology slides to classify meningiomas and predict recurrence risk, reducing dependency on advanced genetic testing.